140 related articles for article (PubMed ID: 37148829)
1. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.
Gutic B; Bozanovic T; Mandic A; Dugalic S; Todorovic J; Dugalic MG; Sengul D; Detanac DA; Sengul I; Detanac D; Kesicioglu T; Soares Junior JM
Clinics (Sao Paulo); 2023; 78():100204. PubMed ID: 37148829
[TBL] [Abstract][Full Text] [Related]
2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
5. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
7. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
9. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
12. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract][Full Text] [Related]
15. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.
Angeles MA; Spagnolo E; Cabarrou B; Pérez-Benavente A; Gil Moreno A; Guyon F; Rychlik A; Migliorelli F; Bataillon G; Navarro AS; Betrian S; Ferron G; Hernández A; Martinez A
Int J Gynecol Cancer; 2023 Jan; 33(1):50-56. PubMed ID: 36446410
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma.
Hsieh SF; Lau HY; Wu HH; Hsu HC; Twu NF; Cheng WF
Int J Environ Res Public Health; 2019 Feb; 16(4):. PubMed ID: 30795566
[TBL] [Abstract][Full Text] [Related]
19. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
20. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Nitecki R; Fleming ND; Fellman BM; Meyer LA; Sood AK; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):660-667. PubMed ID: 33867146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
